What is a stock summary page? Click here for an overview.
Business Description
Bal Pharma Ltd
ISIN : INE083D01012
Compare
Compare
Traded in other countries / regions
524824.India IPO Date
1995-04-20Description
Bal Pharma Ltd is a pharmaceutical company. It is principally engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company specializes in prescription drugs, generic and over-the-counter products, intravenous infusion, and bulk actives. It offers products in dosage forms, such as tablets, capsules, syrups, suspensions, creams, and ointments, to various markets.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.17 | |||||
| Equity-to-Asset | 0.2 | |||||
| Debt-to-Equity | 2.25 | |||||
| Debt-to-EBITDA | 4.73 | |||||
| Interest Coverage | 1.56 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.58 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.9 | |||||
| 3-Year EBITDA Growth Rate | 6 | |||||
| 3-Year EPS without NRI Growth Rate | 13.3 | |||||
| 3-Year FCF Growth Rate | -17.6 | |||||
| 3-Year Book Growth Rate | 6.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.36 | |||||
| 9-Day RSI | 58.03 | |||||
| 14-Day RSI | 57.54 | |||||
| 3-1 Month Momentum % | -20.84 | |||||
| 6-1 Month Momentum % | -26.26 | |||||
| 12-1 Month Momentum % | -11.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | |||||
| Quick Ratio | 0.72 | |||||
| Cash Ratio | 0.12 | |||||
| Days Inventory | 201.46 | |||||
| Days Sales Outstanding | 122.79 | |||||
| Days Payable | 165.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.1 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| Forward Dividend Yield % | 1.1 | |||||
| 5-Year Yield-on-Cost % | 1.1 | |||||
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | -5.78 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 43.52 | |||||
| Operating Margin % | 7.55 | |||||
| Net Margin % | 2.4 | |||||
| FCF Margin % | 3.9 | |||||
| ROE % | 10.81 | |||||
| ROA % | 2.2 | |||||
| ROIC % | 8.93 | |||||
| 3-Year ROIIC % | -3.07 | |||||
| ROC (Joel Greenblatt) % | 12.89 | |||||
| ROCE % | 20.49 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.72 | |||||
| PE Ratio without NRI | 21.96 | |||||
| Shiller PE Ratio | 63.55 | |||||
| Price-to-Owner-Earnings | 20.01 | |||||
| PEG Ratio | 0.95 | |||||
| PS Ratio | 0.54 | |||||
| PB Ratio | 2.45 | |||||
| Price-to-Tangible-Book | 3.24 | |||||
| Price-to-Free-Cash-Flow | 14.13 | |||||
| Price-to-Operating-Cash-Flow | 7.33 | |||||
| EV-to-EBIT | 13.13 | |||||
| EV-to-EBITDA | 9.22 | |||||
| EV-to-Revenue | 0.98 | |||||
| EV-to-FCF | 24.96 | |||||
| Price-to-GF-Value | 1.1 | |||||
| Price-to-Projected-FCF | 1.2 | |||||
| Price-to-Median-PS-Value | 1.09 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.9 | |||||
| Price-to-Graham-Number | 1.76 | |||||
| Earnings Yield (Greenblatt) % | 7.61 | |||||
| FCF Yield % | 6.84 | |||||
| Forward Rate of Return (Yacktman) % | 20 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bal Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 3,029.586 | ||
| EPS (TTM) (₹) | 4.87 | ||
| Beta | 0.82 | ||
| 3-Year Sharpe Ratio | -0.21 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 43.52 | ||
| 14-Day RSI | 57.54 | ||
| 14-Day ATR (₹) | 7.27053 | ||
| 20-Day SMA (₹) | 101.785 | ||
| 12-1 Month Momentum % | -11.95 | ||
| 52-Week Range (₹) | 76.3 - 157.9 | ||
| Shares Outstanding (Mil) | 15.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bal Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bal Pharma Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bal Pharma Ltd Frequently Asked Questions
What is Bal Pharma Ltd(BOM:524824)'s stock price today?
The current price of BOM:524824 is ₹108.62. The 52 week high of BOM:524824 is ₹157.90 and 52 week low is ₹76.30.
When is next earnings date of Bal Pharma Ltd(BOM:524824)?
The next earnings date of Bal Pharma Ltd(BOM:524824) is .
Does Bal Pharma Ltd(BOM:524824) pay dividends? If so, how much?
The Dividend Yield %  of Bal Pharma Ltd(BOM:524824) is 1.1% (As of Today), Highest Dividend Payout Ratio of Bal Pharma Ltd(BOM:524824) was 0.92. The lowest was 0.2. And the median was 0.45. The  Forward Dividend Yield % of Bal Pharma Ltd(BOM:524824) is 1.1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers